Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma
摘要：
Interleukin-2 receptor alpha chain (CD25) is overexpressed by ATL leukemia cells.Daclizumab a humanized monoclonal antibody blocks IL-2 binding to CD25.8mg/kg of daclizumab is required to get ≥95% saturation of CD25 in lymph nodes.Partial responses were observed in patients with chronic and smoldering ATL.The study provides a rationale for high-dose treatment in lymphoid malignancies.
展开
关键词：
Adult T-cell leukemia/lymphoma Daclizumab Human T-cell leukemia virus 1 (HTLV-1) associated ATL Interleukin-2 receptor alpha Monoclonal antibody
DOI：
10.1016/j.clim.2014.09.012
被引量：
年份：
2014
通过文献互助平台发起求助，成功后即可免费获取论文全文。
相似文献
参考文献
引证文献
辅助模式
引用
文献可以批量引用啦~
欢迎点我试用！
